

Grifols announces a strategic investment from GIC of approximately USD 1 billion

- *GIC will invest approximately USD 1 billion to acquire a minority stake in Grifols' US subsidiary Biomat USA, which manages 296 U.S.-based plasma collection centers.*
- *Grifols will maintain control over Biomat's management and operations, and all plasma collected by Biomat will continue to be supplied to Grifols to produce its plasma-derived medicines.*
- *All proceeds from the investment will be used to repay debt, reflecting Grifols' firm commitment to reduce its leverage levels.*
- *This transaction supports Grifols' strategy to expand and strengthen its U.S. plasma center network.*

Barcelona, June 30, 2021.- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare leader with a track record of more than 100 years dedicated to enhancing people's health and well-being and a forerunner in plasma-derived medicines, transfusion diagnostics and hospital pharmacy solutions, and GIC, the sovereign wealth fund of Singapore, have entered into a definitive agreement under which GIC will invest ~USD 1 billion in Grifols' wholly-owned US subsidiary Biomat USA. As part of the transaction, GIC will become a strategic investor in Grifols' business, holding a minority stake in Biomat USA through the acquisition of newly issued non-voting stock.

Biomat is a global leader in plasma collection, with a network of 296 U.S.-based plasma collection centers.

Grifols will continue to oversee all aspects of Biomat's management and operations. All plasma collected by Biomat and its subsidiaries will continue to be supplied to Grifols for the production of plasma-derived medicines, through a long-term plasma supply agreement.

Grifols' leadership in the manufacture of plasma-based medicines, extensive expertise in the expansion and management of plasma centers, market know-how, and outstanding reputation were all key factors in GIC's decision to invest in the company.

As Grifols' co-CEO Víctor Grifols Deu notes, *"We are pleased to welcome GIC as a strategic investor to bolster and expand our U.S. plasma center network, which is a clear competitive advantage. This transaction supports Grifols' business model and our strategy in plasma collection, together with a solid innovation portfolio focused on disease management beyond the therapies based on plasma-derived medicines. With robust demand for Grifols' plasma proteins, our efforts remain centered on doing our best to respond to the needs of patients and healthcare professionals."*

Grifols will apply all proceeds from GIC's investment to repay debt as part of its ongoing commitment to gradually reduce financial leverage. In the first quarter of 2021, Grifols' net financial debt totaled EUR 6,200.5 million¹ and its net financial debt/ EBITDA ratio was 5.1x following the acquisitions of plasma centers from BPL and Kedrion and Grifols' transaction with GigaGen.

The closing of GIC's strategic investment in Grifols is subject to certain conditions, including applicable regulatory authorizations, such as the Committee on Foreign Investment in the United States (CFIUS).

Grifols retained Osborne Clarke, S.L.P and Proskauer Rose, L.L.P as legal advisors for the transaction, and Nomura Securities International, Inc. as sole financial advisor. GIC retained Dechert LLP as legal advisor.

Investor contact:

Investor Relations

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

Media contacts:

Raquel Lumbreras – 659 57 21 85 - Raquel_lumbreras@duomocomunicacion.com

Borja Gómez – 650 40 22 25 - Borja_gomez@duomocomunicacion.com

Duomo Comunicación – **Grifols Press Office**

Tel. +34 91 311 92 89 - 91 311 92 90

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols' economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.

¹ Excluding the impact of IFRS 16

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com



LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.